Literature DB >> 24653971

First report of OXA-48-producing Klebsiella pneumoniae strains in Iran.

Leila Azimi1, Patrice Nordmann2, Abdolaziz Rastegar Lari3, Rémy A Bonnin2.   

Abstract

Carbapenem-resistant Enterobacteriaceae are increasingly reported worldwide and cause therapeutic problem in health care facilities. In this study 28 imipenem-resistant K. pneumoniae were examined for expression of carbapenemases by phenotypic and genotypic methods. Modified Hodge Test (MHT), CarbaNP test were used for phenotypic detection, and PCR using specific primers for the detection of bla OXA-48 -, bla KPC -, bla NDM - and bla VIM -type carbapenemases with specific primers were performed. MHT and CarbaNP tests were positive for all of imipenem-resistant K. pneumoniae. The bla OXA-48 gene was detected in 27/28 isolates. One isolate was positive for the presence of the bla VIM-4 gene. According to our results NP test and MHT have high sensitivity and specificity for detection of those carbapenemases. This study reports the first cases of OXA-48-producing K. pneumoniae in Iran.

Entities:  

Keywords:  CarbaNP test; Klebsiella pneumoniae; MHT; OXA-48; carbapenem

Year:  2014        PMID: 24653971      PMCID: PMC3960935          DOI: 10.3205/dgkh000227

Source DB:  PubMed          Journal:  GMS Hyg Infect Control        ISSN: 2196-5226


Introduction

Carbapenems are often considered as a last therapeutic choice for the treatment of infections due to multidrug-resistant Gram-negative rods [1], [2], [3], [4], [5]. Emergence of carbapenem-resistant Enterobacteriaceae is increasingly reported worldwide and is becoming an important issue in health care systems [4], [6]. Resistance to carbapenems in K. pneumoniae is related to two main mechanisms: i) production of extended-spectrum β-lactamase (cephalosporinase or ESBL) associated with porin loss, and ii) production of carbapenem-hydrolyzing β-lactamase such as Ambler’s class A carbapenemases (KPC-type), class B metallo-β-lactamase (VIM-, NDM- or IMP-type) or class D carbapenemase OXA-48 [1], [4], [6], [7]. A number of phenotypical methods were used for detection of carbapenemases producer strains such as Modified Hodge Test (MHT) according to CLSI recommendations [8]. One new phenotypic method was described for detection of carbapenemases producer bacteria [1]. This test is currently utilized to identify the carbapenemase production in Gram-negative bacteria, with a low cost and high sensitivity and specificity, and was performed for rapid detection (≤2 h) of carbapenemases [1], [2]. CarbaNP test is a biochemical test, applicable to isolated bacterial colonies, and is based on in vitro hydrolysis of a carbapenem compound (imipenem). The OXA-48 carbapenemase was first reported from a Turkish isolates in 2004 [7] but recently the OXA-48-producing Enterobacteriaceae is repeatedly reported from different parts of the world however mostly from Mediterranean countries [9]. The bla has been identified within the Tn1999 composite transposon bracketed by two copies of IS1999 responsible for its mobility and expression [10], [11]. This carbapenemase gene is harbored by an IncL/M-type plasmid in which the Tn1999 was inserted [12]. This highly conjugative plasmid has been found responsible for the widespread of the bla genes [12]. The bla gene is spreading worldwide but not yet reported from Iran. In this study, we report the very first cases of OXA-48-producing K. pneumoniae identified in Iran.

Methods

Bacterial strains and susceptibility testings

In this study, a collection of 28 non-duplicated carbapenem-resistant K. pneumoniae isolated from 18 patients has been analyzed. All of these invasive strains were obtained from clinical specimens taken from patients hospitalized in a burn unit from Motahari Hospital, Teheran, Iran between February to August 2011. More than one K. pneumonia strain was isolated from 10 patients, but different antibiograms were observed in these isolates. On the other hand different specimens were collected from patients in different days after their hospitalization. All of these 28 strains were isolated from infected burn wounds. Fifteen patients received meropenem as monotherapy whereas the three remaining patients received cefepime as monotherapy. These strains were isolated from wounds of burn patients hospitalized in Motahari Hospital (referral center for burn patients in Tehran, Iran) from February to August 2011. These isolates were identified by using the API 20E system (bioMérieux, Marcy l’Etoile, France).

Antibiotic susceptibility testing

The antibiotic susceptibilities of the isolates were determined by the agar disc diffusion method on Mueller-Hinton agar with antibiotic discs MAST Company, UK and interpreted according to Clinical and Laboratory Standards Institute CLSI guidelines [8]. Tested antibiotics included; cefotaxime (30 µg), cefepime (30 µg), imipenem (10 µg), meropenem (10 µg), amoxicillin-clavulanic acid (20/10 µg), aztreonam (30 µg), tobramycin (10 µg), gentamicin (10 µg), amikacin (30 µg), trimethoprim-sulfamethoxazole (1.25/23.75 μg), chloramphenicol (30 µg) and tetracycline (30 µg). MIC of imipenem, meropenem and cefepime were determined by agar dilution method.

Phenotypic methods for detection of carbapenemase

Modified Hodge Test (MHT): This test was conducted according to the CLSI 2011 guidelines for search of carbapenemase production [8]. K. pneumoniae ATCC BAA-1705 were used as positive and K. pneumoniae ATCC BAA-1706 as negative controls. Strains with cloverleaf images of inhibition zone were considered as a carbapenemase-producing K. pneumoniae. Use of boronic acid as a KPC inhibitor: Use of boronic acid (BA) as an inhibitor of KPC in combined-disk test with 400 µg/disc BA was carried out. The stock solution of BA (benzene boronic acid; Sigma-Alderich, Germany) in dimethyl sulfoxcid and distilled water were mixed at a concentration of 20 mg/ml. From this solution 20 µl (containing 400 µg/disk) was added on to commercially meropenem disks. The test was considered positive when the inhibition zone diameter around the disk containing meropenem and boronic acid was ≥5 mm compared with meropenem alone. CarbaNP test (Carbapenemase Nordmann-Poirel test): One loop of strains was resuspended to Tris-HCL mmol/L as a lysis buffer from antibiogram plates, vortex for one minute and then incubated at room temperature for 30 minutes. Bacterial suspension was centrifuged at 10,000 xg at room temperature for 5 minutes. 30 µl of supernatant was mixed in 96 tray with 100 µl of imipenem monohydrate solusion (3 mg per ml) pH 7.8, phenolred solution and 0.1 mmol/L ZnSO4.

PCR amplification and sequencing

Rapid DNA extractions were prepared by boiling extraction. PCR experiments were performed using standard conditions and specific primers to search for carbapenemase genes that have been identified previously in K. pneumoniae i.e. the bla, bla, bla, bla and bla8 (Table 1 (Tab. 1)). Direct sequencing of PCR amplified products was carried out using ABI 3730X capillary sequencer (Genfanavaran, Macrogen, Seoul, Korea).
Table 1

Primers sequencing

Results

Among these 28 isolates, all were resistant to broad-spectrum cephalosporins, carbapenems (imipenem, ertapenem, meropenem), trimethoprim-sulfamethoxazole and quinolones (Table 2 (Tab. 2)). Some of them remained susceptible to amikacin and/or gentamicin, respectively (resistance rates for gentamicin at 90% and resistance rates to chloramphenicol, tetracycline and amikacin at 82%, 86% and 79%, respectively). Antimicrobial susceptibility testing results showed that all of the strains were resistant to imipenem, meropenem, and cefepime. Nine and eleven out of 28 isolates had MIC more than 64 µg/ml against imipenem and meropenem, respectively. Nineteen of 28 strains had MIC more than 128 µg/ml against cefepime.
Table 2

Antibiotic susceptibility patterns

Eight different antimicrobial resistant patterns were observed among isolates likely indicating several clone are disseminating within the burn unit (Table 2 (Tab. 2)). The results show that MHT and CarbaNP tests were positive for all carbapenem-resistant K. pneumoniae but none of them showed at least 5 mm increase in diameter of inhibition zone around meropenem plus BA comparison with meropenem alone. PCR analysis following by sequencing showed the presence of the bla gene in 27 isolates (Figure 1 (Fig. 1)).
Figure 1

PCR amplification fragments for detection of OXA-48 gene among Klebsiella pneumoniae isolates

M: 1kb DNA size marker; lane 1: Positive control; lane 2 and 3: Positive strains.

Whereas a single isolate was positive for bla gene. No bla, bla or bla genes were detected in this collection.

Discussion

Different K. pneumionieae with different antibiograms were isolated from one patient. Despite the K. pneumonia were isolated with same antibiogram among different patients. Isolates with same antibiotic-resistant pattern may derive from identical clone. The OXA-48-type carbapenemases have been reported from France [4], Spain [6], Netherlands [13], Lebanon [4], Morocco [14] and Oman [15] and is becoming one of the main resistance mechanisms in K. pneumoniae [10]. The bla gene has been identified in 90.5% of K. pneumoniae isolates in six different Spanish hospitals [6]. To best of our knowledge, this study constitutes the very first report of OXA-48-producing K. pneumoniae from Iran. Detection of OXA-48-producing Enterobacteriaceae can be important, because such strains may often remain susceptible to third and fourth generation cephalosporins and monobactams and also this characteristic can make difficulty for detection of them [10]. After the recent identification of the bla and the bla genes in a burn unit in Teheran, the identification of the bla carbapenemase gene is worrisome [5], [16]. Overall, this study identifies for the first time OXA-48-producing K. pneumoniae strains from Iran. Therefore, the spread of OXA-48 producers may be more widespread than expected and can be expected in any countries of the Middle East.

Notes

Competing interests

The authors declare that they have no competing interests.

Acknowledgment

This study was supported by a grant (M/T 91-04-134-20187) from Iran University of Medical Sciences, Tehran, Iran.
  17 in total

1.  Nosocomial occurrence of OXA-48-producing enterobacterial isolates in a Moroccan hospital.

Authors:  Constantin Hays; Amina Benouda; Laurent Poirel; Mostafa Elouennass; Patrice Nordmann
Journal:  Int J Antimicrob Agents       Date:  2012-04-21       Impact factor: 5.283

2.  NDM-1, OXA-48 and OXA-181 carbapenemase-producing Enterobacteriaceae in Sultanate of Oman.

Authors:  L Dortet; L Poirel; F Al Yaqoubi; P Nordmann
Journal:  Clin Microbiol Infect       Date:  2012-03-08       Impact factor: 8.067

3.  Functional characterization of IS1999, an IS4 family element involved in mobilization and expression of beta-lactam resistance genes.

Authors:  Daniel Aubert; Thierry Naas; Claire Héritier; Laurent Poirel; Patrice Nordmann
Journal:  J Bacteriol       Date:  2006-09       Impact factor: 3.490

4.  A set of multiplex PCRs for genotypic detection of extended-spectrum β-lactamases, carbapenemases, plasmid-mediated AmpC β-lactamases and OXA β-lactamases.

Authors:  Guido M Voets; A C Fluit; Jelle Scharringa; James Cohen Stuart; Maurine A Leverstein-van Hall
Journal:  Int J Antimicrob Agents       Date:  2011-02-25       Impact factor: 5.283

5.  Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France.

Authors:  Gaelle Cuzon; Jocelyne Ouanich; Remy Gondret; Thierry Naas; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

6.  Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge.

Authors:  C Navarro-San Francisco; M Mora-Rillo; M P Romero-Gómez; F Moreno-Ramos; A Rico-Nieto; G Ruiz-Carrascoso; R Gómez-Gil; J R Arribas-López; J Mingorance; J R Paño-Pardo
Journal:  Clin Microbiol Infect       Date:  2012-12-12       Impact factor: 8.067

Review 7.  OXA-48-like carbapenemases: the phantom menace.

Authors:  Laurent Poirel; Anaïs Potron; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2012-04-11       Impact factor: 5.790

8.  Emergence of OXA-48-producing Klebsiella pneumoniae and the novel carbapenemases OXA-244 and OXA-245 in Spain.

Authors:  Jesús Oteo; Juan Manuel Hernández; Mateu Espasa; Ana Fleites; David Sáez; Verónica Bautista; María Pérez-Vázquez; Ma Dolores Fernández-García; Alberto Delgado-Iribarren; Isabel Sánchez-Romero; Luisa García-Picazo; Ma Dolores Miguel; Sonia Solís; Esteban Aznar; Gloria Trujillo; Concepción Mediavilla; Dionisia Fontanals; Susana Rojo; Ana Vindel; José Campos
Journal:  J Antimicrob Chemother       Date:  2012-10-02       Impact factor: 5.790

9.  First report of New Delhi metallo-beta-lactamase-1-producing Klebsiella pneumoniae in Iran.

Authors:  Fereshteh Shahcheraghi; Saman Nobari; Fatemeh Rahmati Ghezelgeh; Siavash Nasiri; Parviz Owlia; Vajihe Sadat Nikbin; Abbas Ali Imani Fooladi
Journal:  Microb Drug Resist       Date:  2012-09-17       Impact factor: 3.431

Review 10.  Strategies for identification of carbapenemase-producing Enterobacteriaceae.

Authors:  Patrice Nordmann; Laurent Poirel
Journal:  J Antimicrob Chemother       Date:  2012-10-26       Impact factor: 5.790

View more
  13 in total

1.  Emergence of co-existence of blaNDM with rmtC and qnrB genes in clinical carbapenem-resistant Klebsiella pneumoniae isolates in burning center from southeast of Iran.

Authors:  Somayeh Kiaei; Mohammad Moradi; Hossein Hosseini Nave; Zahra Hashemizadeh; Majid Taati-Moghadam; Davood Kalantar-Neyestanaki
Journal:  Folia Microbiol (Praha)       Date:  2018-07-12       Impact factor: 2.099

2.  Characterization of Carbapenemases in Extensively Drug Resistance Acinetobacter baumannii in a Burn Care Center in Iran.

Authors:  Leila Azimi; Malihe Talebi; Mohammad-Reza Pourshafie; Parviz Owlia; Abdolaziz Rastegar Lari
Journal:  Int J Mol Cell Med       Date:  2015

Review 3.  Dissemination of carbapenemases producing Gram negative bacteria in the Middle East.

Authors:  Abed Zahedi Bialvaei; Hossein Samadi Kafil; Hamed Ebrahimzadeh Leylabadlo; Mohammad Asgharzadeh; Mohammad Aghazadeh
Journal:  Iran J Microbiol       Date:  2015-10

Review 4.  The threat of carbapenem-resistant gram-negative bacteria in a Middle East region.

Authors:  Effat Davoudi-Monfared; Hossein Khalili
Journal:  Infect Drug Resist       Date:  2018-10-17       Impact factor: 4.003

Review 5.  Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods.

Authors:  Chang-Ro Lee; Jung Hun Lee; Kwang Seung Park; Young Bae Kim; Byeong Chul Jeong; Sang Hee Lee
Journal:  Front Microbiol       Date:  2016-06-13       Impact factor: 5.640

6.  EXTENDED-SPECTRUM BETA-LACTAMASE PRODUCING GRAM NEGATIVE BACTERIA IN IRAN: A REVIEW.

Authors:  Hamed Ebrahimzadeh Leylabadlo; Tala Pourlak; Abed Zahedi Bialvaei; Mohammad Aghazadeh; Mohammad Asgharzadeh; Hossein Samadi Kafil
Journal:  Afr J Infect Dis       Date:  2017-06-08

Review 7.  Understanding the Epidemiology of Multi-Drug Resistant Gram-Negative Bacilli in the Middle East Using a One Health Approach.

Authors:  Iman Dandachi; Amer Chaddad; Jason Hanna; Jessika Matta; Ziad Daoud
Journal:  Front Microbiol       Date:  2019-08-23       Impact factor: 5.640

8.  Evaluation of Phenotypic and Genotypic Characteristics of Carbapnemases-producing Enterobacteriaceae and Its Prevalence in a Referral Hospital in Tehran City.

Authors:  Kosar Jalalvand; Nasrin Shayanfar; Fereshteh Shahcheraghi; Elahe Amini; Mahsa Mohammadpour; Pegah Babaheidarian
Journal:  Iran J Pathol       Date:  2020-02-28

9.  Detection of bla CTX-M15 and bla OXA-48 genes in Gram-negative isolates from neonatal sepsis in central of Iran.

Authors:  Taiebeh Shakiba; Alireza Sadeghnia; Vajihe Karbasizade
Journal:  Iran J Microbiol       Date:  2019-08

10.  Dissemination Pattern of Multidrug Resistant Carbapenemase Producing Klebsiella pneumoniae Isolates Using Pulsed-Field Gel Electrophoresis in Southwestern Iran.

Authors:  Zahra Hashemizadeh; Zahra Hosseinzadeh; Negar Azimzadeh; Mohammad Motamedifar
Journal:  Infect Drug Resist       Date:  2020-03-30       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.